Included in the formulation
АТХ:A.10.B.X Other hypoglycemic drugs
Pharmacodynamics:The agonist of human glucagon-like peptide-1, stimulates glucose-dependent insulin secretion in pancreatic β-cells. Competitively suppresses excessive glucose-dependent secretion of glucagon. When hypoglycemia reduces the secretion of insulin, without affecting the production of glucagon. Slightly delays gastric emptying, reduces hunger and energy consumption, thereby reducing the amount of fat tissue.
Pharmacokinetics:After subcutaneous administration, the bioavailability is about 55%. The maximum concentration in the blood plasma is reached after 24-72 hours. The connection with plasma proteins is more than 98%.
Metabolism in the liver.
The elimination half-life is 120 hours. Elimination by the kidneys.
Indications:It is used for the treatment of diabetes mellitus II type in combination with oral hypoglycemic agents.
IV.E10-E14.E11 Non-insulin-dependent diabetes mellitus
Contraindications:
Diabetes I type, severe cardiac, hepatic and renal insufficiency, diabetic ketoacidosis, paresis of the stomach, inflammatory bowel disease, individual intolerance, children under 18, pregnancy and lactation.
Carefully:
Cardiac, renal and hepatic insufficiency of mild and moderate severity, age over 75 years.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Subcutaneously once a week, preferably at the same time. The dose is calculated individually according to the level of glucose in the blood plasma. The initial dose is 0.75 mg, if necessary, after one week the dose is doubled.
The highest daily dose: 1.5 mg.
The highest single dose: 1.5 mg.
Side effects:Central and peripheral nervous system: lethargy, dizziness, depression, emotional lability.
Digestive system: anorexia, decreased appetite, acute pancreatitis, diarrhea, nausea, diarrhea, belching, bloating, gastroesophageal reflux, when combined with derivatives of sulfonylureas - hypoglycemia.
urinary system: renal failure, polyuria.
Allergic reactions.
Overdose:Nausea and vomiting.
Treatment is symptomatic.
Interaction:It is combined with insulin and oral hypoglycemic agents.
Special instructions:When treated in combination with oral hypoglycemic agents are not recommended driving vehicles and working with moving mechanisms (in connection with the possible risk of hypoglycemia).